

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	6964663
<b>Application Number:</b>	10531560
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	3534
<b>Title of Invention:</b>	TREATMENT OF OSTEOARTHRITIS
<b>First Named Inventor/Applicant Name:</b>	Ian Alexander Shiels
<b>Customer Number:</b>	27683
<b>Filer:</b>	Mark D. Moore/Marty Miles
<b>Filer Authorized By:</b>	Mark D. Moore
<b>Attorney Docket Number:</b>	36672.6
<b>Receipt Date:</b>	05-FEB-2010
<b>Filing Date:</b>	27-JAN-2006
<b>Time Stamp:</b>	23:18:46
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$810
RAM confirmation Number	13021
Deposit Account	081394
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)



Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Continued Examination (RCE)	36672_6_RCE.pdf	769798	no	3
			783e0f9dd5f1c672a33d13f57ecc206049f9e48b		
Warnings:					
Information:					
2	Amendment Submitted/Entered with Filing of CPA/RCE	36672_RCE_Accompany.pdf	2320837	no	58
			2030a7a7b4ba95801c943b8c5eb493da76642169		
Warnings:					
Information:					
3	NPL Documents	NPL_Anaya_Pulmonary_Involvement.PDF	229704	no	1
			1717c331e2f43806528eeb2d327470b7193cca9e		
Warnings:					
Information:					
4	NPL Documents	NPL_Arumugam_A_Small_Molecule_C5a.PDF	1962457	no	9
			cadd28170689680ea53c95c6ef8e77b9ae803308		
Warnings:					
Information:					
5	NPL Documents	NPL_Arumugam_Protective_Effects.PDF	1864996	no	8
			1cdd2f9e80aa71775da5498c41a59c7cb380e0e7		
Warnings:					
Information:					
6	NPL Documents	NPL_Baskaran_Dynamics_of_Tissue.PDF	2100933	no	9
			05795efa47165a3b301d45e63b5e23a781929452		
Warnings:					
Information:					
7	NPL Documents	NPL_Beams.pdf	2094646	no	12
			1d2d85ecc1ada5ada1ee7e7f472f5f7302501726		
Warnings:					
Information:					
8	NPL Documents	NPL_Benoit Studies_On_Sensitivity.PDF	1576276	no	8
			ca9c4ce081da6d44984b52bb21655ff1f62f3734		
Warnings:					
Information:					



9	NPL Documents	NPL_Bernadelli_etal_Trends_and_Perpctives.PDF	4230050	no	21
			5c56530bf65dc9fe0ffea7a2628c95db1a14476		
Warnings:					
Information:					
10	NPL Documents	NPL_Bertrand_CCR3_Blockade.PDF	2027274	no	10
			d49f13766cdaccd27535d9b6deac9a7fce71b4bd		
Warnings:					
Information:					
11	NPL Documents	NPL_Bodansky_Introduction_of_Amine.PDF	2860861	no	19
			a5ef59f22c782cb2a3b625f084fa7af43c8872a7		
Warnings:					
Information:					
12	NPL Documents	NPL_Brady_Large_Scale.PDF	1851584	no	6
			c72123d4e74fc85d311d683ffa0c7c5d1bbf7c		
Warnings:					
Information:					
13	NPL Documents	NPL_Cain_Modulation_of_LigandSelectivity.PDF	1622694	no	9
			d307398374ac49969aa4e20bd88382d5150d206f		
Warnings:					
Information:					
14	NPL Documents	NPL_Chan_Basic_Procedures.PDF	4445833	no	19
			40111c1e59dfa16485018617668153c160ff5015		
Warnings:					
Information:					
15	NPL Documents	NPL_Cheng_Trends_Perspectives_1995.PDF	3102513	no	18
			4f78c4c4ba5ac975569925bcb4b4b90a895b5d81		
Warnings:					
Information:					
16	NPL Documents	NPL_Dinarelli.pdf	329251	no	5
			7c3400c5cfa50f4b28cee8f29ee4b0de6dfa3dad		
Warnings:					
Information:					
17	NPL Documents	NPL_Diop.pdf	1929873	no	10
			42a7ab110717c17db5fc914bd550282b2e2bb978		
Warnings:					
Information:					



18	NPL Documents	NPL_Fields_Solid_Phase.PDF	7371926	no	28
			d78bfd32f12b7536a28a9575c42d7add15d11f97		
Warnings:					
Information:					
19	NPL Documents	NPL_Fukunaga_A_Novel.PDF	1840654	no	9
			3f8f63dcd46d30c0c3c3fa3ca60116d05c03670f		
Warnings:					
Information:					
20	NPL Documents	NPL_Galatis_Trends_and_Perspectives.PDF	3732280	no	22
			2dc8b3d8538fd2ff29d5b58402d3269805d389fc		
Warnings:					
Information:					
21	NPL Documents	NPL_Gao_RecentAdvances.PDF	586436	no	14
			3414018c0b2f6a2c8d0672a3573327a7116bb1a4		
Warnings:					
Information:					
22	NPL Documents	NPL_Gaudilliere_Trends_Perspectives_2001.PDF	4539770	no	26
			2e981318c1c407adc2d4002f56f3bae2f73d4b4d		
Warnings:					
Information:					
23	NPL Documents	NPL_Gaudilliere_Trends_Perspectives_2000.PDF	4293100	no	26
			2702683901ad2a3afc8ca82b98530c94a11f6b6b		
Warnings:					
Information:					
24	NPL Documents	NPL_Harkin.pdf	1925050	no	11
			0da60b0438ecac92ad643b274d28137dba1610a6		
Warnings:					
Information:					
25	NPL Documents	NPL_Haynes_Inhibition.PDF	980028	no	5
			549f501d82587269458d1044e68008af61c693ec		
Warnings:					
Information:					
26	NPL Documents	NPL_Heller.pdf	2363092	no	10
			37a2f6b5f8ee2c87f81bb8f7c6cccd3007d5c158		
Warnings:					
Information:					



27	NPL Documents	NPL_Ikeda_Simvastatin_Attenuates.PDF	1277713	no	7
			2b66eeb15f348223dd56d3e64471ea3c65866990		
Warnings:					
Information:					
28	NPL Documents	NPL_Johnson_Heterotrimeric.PDF	2707250	no	11
			f2f6fc81b7f477d97dee279e93ea368470ed7629		
Warnings:					
Information:					
29	NPL Documents	NPL_Makrides_Therapeutic_Inhibition.PDF	7370618	no	29
			3eb7eb47a1fd4a6b03e261e2e106cc5953328502		
Warnings:					
Information:					
30	NPL Documents	NPL_Morikis.pdf	2089339	no	11
			e47d6782c1005617abf4e44ce41f28e2bc8698d		
Warnings:					
Information:					
31	NPL Documents	NPL_Morris_Hapten_Induces.PDF	2801940	no	9
			b725ecaa6c47305bf933d81e0fc2055cbbc31739		
Warnings:					
Information:					
32	NPL Documents	NPL_Owen_Chemokine_Receptors.PDF	2214247	no	10
			5c81ad5e62f27b06890c4474ef6f33db255f1de4		
Warnings:					
Information:					
33	NPL Documents	NPL_Paczkowski_pharmacological_Characterization.PDF	1468864	no	6
			1002fa26af6037f350a31ca7450f14b7b0d35007		
Warnings:					
Information:					
34	NPL Documents	NPL_Piccolo_Chemotactic_Mediator.PDF	1303087	no	7
			99e04d9a775b21b7a2205fe57192759f434724e4		
Warnings:					
Information:					
35	NPL Documents	NPL_Reid.pdf	237719	no	2
			bf7dc62e4b374362075f35614e2d30e064026c51		
Warnings:					
Information:					



36	NPL Documents	NPL_Roschmann_Pulmonary_Fibrosis.PDF	206322	no	1
			f43a1c2f664668a52fc7b399bba6d52718a95eba		
Warnings:					
Information:					
37	NPL Documents	NPL_Schmid_Requirement_for.PDF	1365219	no	6
			2512803e83b763fb73c613c445c0158c694e5fd4		
Warnings:					
Information:					
38	NPL Documents	NPL_Schuda_A_Short.PDF	935232	no	3
			99f10252ae33975ed6bf1d9971f9ebf29a59fd98		
Warnings:					
Information:					
39	NPL Documents	NPL_Short_Effects_of.PDF	818646	no	4
			a86b7f66803bae8b2cb7771f91bbd0c49ff49798		
Warnings:					
Information:					
40	NPL Documents	NPL_Smith_Organic_Synthesis.PDF	598081	no	5
			5ef386e4262658912374ad228445c82edf6b60f5		
Warnings:					
Information:					
41	NPL Documents	NPL_Steinauer_Studies_on.PDF	857561	no	4
			d27f25148adcc26e4d45e0595f8791583adecef4		
Warnings:					
Information:					
42	NPL Documents	NPL_Stewart_Current_Therapy.PDF	1122137	no	5
			4a3c84ca560d6a01e7fc474d7ad6294c6232412a		
Warnings:					
Information:					
43	NPL Documents	NPL_Strachan_Inhibition_of.PDF	1915686	no	9
			2bee6d8da2f4b98b9aff7053ecc645d318d15f22		
Warnings:					
Information:					
44	NPL Documents	NPL_Strieter_Effects_of.PDF	490293	no	2
			e2843c9d124297895f1956913e1335ff6d141d5e		
Warnings:					
Information:					



45	NPL Documents	NPL_Szebeni.pdf	2134014	no	9
			b0869a6dc7dff2b6451adcd2f200e89b4b7e2cf		
Warnings:					
Information:					
46	NPL Documents	NPL_Taylor_Regulations_of_the.PDF	1974301	no	10
			e2693bf5e1ca298bfef2e96a0fff30967b074e27		
Warnings:					
Information:					
47	NPL Documents	NPL_Toulouse.pdf	1622761	no	7
			5fb5a0ca96bc246070d7aef825c35954643f5ec6		
Warnings:					
Information:					
48	NPL Documents	NPL_VanaAssche_Emerging_Drugs.PDF	2369716	no	11
			5ec73f678efea22b905907e02126ef3037169a8d		
Warnings:					
Information:					
49	NPL Documents	NPL_Wong_Small_Molecular.PDF	2179937	no	9
			5228e8372524758dfbf99e68fb5f464107591af5		
Warnings:					
Information:					
50	NPL Documents	NPL_Woodruff_Species_Dependence.PDF	1107265	no	7
			0e4f9b49c2159176175691a5ff93877362b4e607		
Warnings:					
Information:					
51	NPL Documents	NPL_Mita.pdf	2129518	no	10
			36e69b05f276ec169fa2e9f38af8c9c5e8c7a649		
Warnings:					
Information:					
52	NPL Documents	NPL_Piccolo_Role_of.PDF	2825893	no	15
			bc9991a7a69230a0e4c0224811c5db0046960418		
Warnings:					
Information:					
53	Information Disclosure Statement (IDS) Filed (SB/08)	36672_6_IDS1.pdf	1102098	no	8
			89b68b07e72d6c6836da8750e91abd142ebee4fe		
Warnings:					
Information:					



A U.S. Patent Number Citation or a U.S. Publication Number Citation is required in the Information Disclosure Statement (IDS) form for autoloading of data into USPTO systems. You may remove the form to add the required data in order to correct the Informational Message if you are citing U.S. References. If you chose not to include U.S. References, the image of the form will be processed and be made available within the Image File Wrapper (IFW) system. However, no data will be extracted from this form. Any additional data such as Foreign Patent Documents or Non Patent Literature will be manually reviewed and keyed into USPTO systems.

54	Fee Worksheet (PTO-875)	fee-info.pdf	30002	no	2
			b747f2b62f3a64661cacd24380ff63a8f9d0432		

**Warnings:**

**Information:**

<b>Total Files Size (in bytes):</b>	110207375
-------------------------------------	-----------

**This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.**

**New Applications Under 35 U.S.C. 111**

**If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.**

**National Stage of an International Application under 35 U.S.C. 371**

**If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.**

**New International Application Filed with the USPTO as a Receiving Office**

**If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.**